PL1723172T3 - Ciekły preparat erytropoetyny - Google Patents

Ciekły preparat erytropoetyny

Info

Publication number
PL1723172T3
PL1723172T3 PL05707735T PL05707735T PL1723172T3 PL 1723172 T3 PL1723172 T3 PL 1723172T3 PL 05707735 T PL05707735 T PL 05707735T PL 05707735 T PL05707735 T PL 05707735T PL 1723172 T3 PL1723172 T3 PL 1723172T3
Authority
PL
Poland
Prior art keywords
erythropoietin
liquid formulation
epo
formulation
erythropoietin liquid
Prior art date
Application number
PL05707735T
Other languages
English (en)
Inventor
Christof Schumann
Jan-Ole Hesse
Original Assignee
Bioceuticals Arzneimittel Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioceuticals Arzneimittel Ag filed Critical Bioceuticals Arzneimittel Ag
Publication of PL1723172T3 publication Critical patent/PL1723172T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL05707735T 2004-03-10 2005-03-10 Ciekły preparat erytropoetyny PL1723172T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004011663A DE102004011663B4 (de) 2004-03-10 2004-03-10 Erythropoietin-Flüssigformulierung
EP05707735A EP1723172B1 (de) 2004-03-10 2005-03-10 Erythropoietin-flüssigformulierung
PCT/EP2005/002551 WO2005087804A1 (de) 2004-03-10 2005-03-10 Erythropoietin-flüssigformulierung

Publications (1)

Publication Number Publication Date
PL1723172T3 true PL1723172T3 (pl) 2007-12-31

Family

ID=34895145

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05707735T PL1723172T3 (pl) 2004-03-10 2005-03-10 Ciekły preparat erytropoetyny

Country Status (13)

Country Link
US (1) US7767644B2 (pl)
EP (2) EP1806361B1 (pl)
JP (1) JP4887281B2 (pl)
AT (2) ATE481419T1 (pl)
CA (1) CA2558985C (pl)
CY (1) CY1106954T1 (pl)
DE (4) DE202004020676U1 (pl)
DK (1) DK1723172T3 (pl)
ES (1) ES2292103T3 (pl)
PL (1) PL1723172T3 (pl)
PT (1) PT1723172E (pl)
SI (1) SI1723172T1 (pl)
WO (1) WO2005087804A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102186490B (zh) * 2008-08-15 2015-07-29 硬木药品公司 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂
CA2770077A1 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
TR201711271T4 (tr) 2010-02-17 2019-02-21 Ironwood Pharmaceuticals Inc Gastrointestinal Bozukluklar İçin Tedaviler
PL2603232T3 (pl) 2010-08-11 2020-05-18 Ironwood Pharmaceuticals, Inc. Stabilne formulacje linaklotydu
CN104053449B (zh) 2011-08-17 2016-12-07 硬木药品公司 胃肠疾患的治疗
MX352823B (es) 2011-10-28 2017-12-04 Integritybio Inc Formulaciones de proteinas que contienen aminoacidos.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
US20030162711A1 (en) * 1996-04-24 2003-08-28 Soren Bjorn Pharmaceutical formulation
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
DE19856443A1 (de) 1998-12-08 2000-06-21 Centeon Pharma Gmbh Stabilisiertes Antithrombin III-Präparat
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
IL145816A0 (en) * 1999-04-09 2002-07-25 Ortho Mcneil Pharm Inc Pharmaceutical compositions of erythropoietin
WO2001007086A1 (en) * 1999-07-22 2001-02-01 Aventis Pharmaceuticals, Inc. Preserved pharmaceutical formulations
BRPI0110914B8 (pt) * 2000-05-15 2021-05-25 Hoffmann La Roche 'composição farmacêutica líquida, processo para preparação da mesma e uso de uma composicão farmacêutica'
US20040022792A1 (en) * 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH

Also Published As

Publication number Publication date
SI1723172T1 (sl) 2007-12-31
ATE481419T1 (de) 2010-10-15
JP2007536215A (ja) 2007-12-13
EP1723172A1 (de) 2006-11-22
ES2292103T3 (es) 2008-03-01
DE502005010276D1 (de) 2010-10-28
DE502005001187D1 (de) 2007-09-20
DE102004011663B4 (de) 2006-04-27
CA2558985C (en) 2012-09-25
EP1806361B1 (de) 2010-09-15
US7767644B2 (en) 2010-08-03
EP1723172B1 (de) 2007-08-08
CY1106954T1 (el) 2012-09-26
WO2005087804A1 (de) 2005-09-22
DK1723172T3 (da) 2007-12-27
CA2558985A1 (en) 2005-09-22
US20080039371A1 (en) 2008-02-14
DE202004020676U1 (de) 2005-11-10
EP1806361A1 (de) 2007-07-11
PT1723172E (pt) 2007-10-29
ATE369382T1 (de) 2007-08-15
JP4887281B2 (ja) 2012-02-29
DE102004011663A1 (de) 2005-09-29

Similar Documents

Publication Publication Date Title
CY1106954T1 (el) Υγρο σκευασμα ερυθροποιητινης
WO2000034317A3 (en) Method for reducing immunogenicity of proteins
WO2003064449A3 (en) Bioactive keratin peptides
ATE292473T1 (de) Thymosin beta 4 stimuliert wundheilung
CN103209678A (zh) 用于改进人类皮肤、毛发和/或指甲的健康的胶原蛋白水解物
WO2006004736A3 (en) Stable liquid and lyophilized formulation of proteins
WO2004037861A3 (en) Neutralizing antibodies against gdf-8 and uses therefor
WO2001052875A8 (en) Vegf-d/vegf-c/vegf peptidomimetic inhibitor
WO2004073616A3 (en) Elastin digest compositions and methods utilizing same
EP2385056A3 (en) Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
CN100444894C (zh) 利用肌动蛋白结合肽促进毛发生长的方法和组合物
EP0744408A3 (en) Rhesus ob protein and DNA
WO2001005810A3 (de) CYCLISCHE PEPTIDDERIVATE ALS INHIBITOREN DES INTEGRINS αvβ¿6?
WO2002058589A3 (en) Agents and methods for promoting bone growth
DE50012415D1 (de) Zubereitungen zur atraumatischen nagelentfernung
ATE493966T1 (de) Mittel zur förderung der hautkollagenproduktion
WO2003082897A3 (en) Synthetic active peptide fragments
NO20003888L (no) Anti-enzympreparater omfattende etylendiamindiravsyre
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells
WO2004032863A3 (en) Oral formulations for proteins and polypeptides
EP1226752A4 (en) NON-HUMAN TRANSGENIC MAMMALS FOR CONTROLLING CHANGE IN CALCIUM ION CONCENTRATION IN CELLS
WO2001098355A3 (en) Cgi-69 compositions and methods of use
WO2002012336A3 (en) TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE
WO2001032693A3 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
Ogasahara et al. The uptake of basic amino acids into fibroblasts was enhanced by PCA.